Last update 15 Mar 2025

Bemnifosbuvir/Ruzasvir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC
Target
NS5A x NS5B polymerase
Mechanism
NS5A inhibitors(Nonstructural protein 5A inhibitors), NS5B polymerase inhibitors(Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors)
Therapeutic Areas
Infectious DiseasesDigestive System Disorders
Active Indication
Hepatitis C, Chronic
Inactive Indication-
Originator Organization
Atea Pharmaceuticals, Inc.Atea Pharmaceuticals, Inc.
Active Organization
Atea Pharmaceuticals, Inc.Atea Pharmaceuticals, Inc.
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC49H55FN10O7S
InChIKeyAXWDHVUJXNOWCC-RAEGKSCOSA-N
CAS Registry1613081-64-3
View All Structures (2)

Related

3
Clinical Trials associated with Bemnifosbuvir/Ruzasvir
NCT06868264
/ Not yet recruitingPhase 3
Phase 3, Randomized, Controlled, Open-label Study to Compare the Efficacy and Safety of Bemnifosbuvir-Ruzasvir Fixed-dose Combination (BEM/RZR FDC) Versus Sofosbuvir-Velpatasvir Fixed-dose Combination (SOF/VEL FDC) in Subjects with Chronic Hepatitis C Virus (HCV) Infection
NCT06356194
/ CompletedPhase 1
A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Drug-Drug Interaction Potential Between Bemnifosbuvir/Ruzasvir and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy®) in Healthy Adult Subjects
NCT06204679
/ CompletedPhase 1
A Phase 1, Open-Label Study to Assess Comparative Bioavailability and Effect of Food on a Prototype Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir Versus Individual Dosage Forms Taken Concomitantly in Healthy Adult Subjects
100 Clinical Results associated with Bemnifosbuvir/Ruzasvir
Login to view more data
100 Translational Medicine associated with Bemnifosbuvir/Ruzasvir
Login to view more data
100 Patents (Medical) associated with Bemnifosbuvir/Ruzasvir
Login to view more data
100 Deals associated with Bemnifosbuvir/Ruzasvir
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatitis C, ChronicPhase 3-
Atea Pharmaceuticals, Inc.Atea Pharmaceuticals, Inc.
01 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free